These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29571585)

  • 1. Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer.
    Kang HW; Seo SP; Byun YJ; Piao XM; Kim YH; Jeong P; Ha YS; Kim WT; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):274-280. PubMed ID: 29571585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
    Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer.
    Li Q; Li C; Chen J; Liu P; Cui Y; Zhou X; Li H; Zu X
    Urol Oncol; 2018 Jun; 36(6):310.e15-310.e22. PubMed ID: 29605462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.
    Kim WJ; Kim EJ; Kim SK; Kim YJ; Ha YS; Jeong P; Kim MJ; Yun SJ; Lee KM; Moon SK; Lee SC; Cha EJ; Bae SC
    Mol Cancer; 2010 Jan; 9():3. PubMed ID: 20059769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study.
    Spagnuolo M; Costantini M; Ferriero M; Varmi M; Sperduti I; Regazzo G; Cicchillitti L; Díaz Méndez AB; Cigliana G; Pompeo V; Russo A; Laquintana V; Mastroianni R; Piaggio G; Anceschi U; Brassetti A; Bove A; Tuderti G; Flammia RS; Gallucci M; Simone G; Rizzo MG
    J Exp Clin Cancer Res; 2020 Apr; 39(1):68. PubMed ID: 32303246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
    Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
    Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling.
    Kawakami K; Enokida H; Tachiwada T; Gotanda T; Tsuneyoshi K; Kubo H; Nishiyama K; Takiguchi M; Nakagawa M; Seki N
    Oncol Rep; 2006 Sep; 16(3):521-31. PubMed ID: 16865252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of spindle and kinetochore- associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer.
    Jiang S; Tian F; Wang Q; Cheng W; Wang L; Wang Y; Sun W
    Cancer Biomark; 2018; 22(3):543-549. PubMed ID: 29865039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of zinc finger E-box binding homeobox 1 and transforming growth factor-beta2 expression in bladder cancer tissue in comparison with healthy adjacent tissue.
    Mahdavinezhad A; Yadegarazari R; Mousavi-Bahar SH; Poorolajal J; Jafari M; Amirzargar MA; Effatpanah H; Saidijam M
    Investig Clin Urol; 2017 Mar; 58(2):140-145. PubMed ID: 28261684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer.
    Jiang X; Du L; Duan W; Wang R; Yan K; Wang L; Li J; Zheng G; Zhang X; Yang Y; Wang C
    Oncotarget; 2016 Jun; 7(24):36733-36742. PubMed ID: 27167342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.
    Nishiyama N; Kitamura H; Maeda T; Takahashi S; Masumori N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2013 Nov; 43(11):1124-31. PubMed ID: 23980236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer.
    Szarvas T; vom Dorp F; Niedworok C; Melchior-Becker A; Fischer JW; Singer BB; Reis H; Bánkfalvi Á; Schmid KW; Romics I; Ergün S; Rübben H
    BJU Int; 2012 Sep; 110(6 Pt B):E308-17. PubMed ID: 22500655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling Nutritional Status Score Evaluates Prognosis in Patients With Non-Muscle Invasive Bladder Cancer.
    Huang J; Zhao L; Wang K; Sun J; Tai S; Hua R; Yu Y; Fan Y
    Cancer Control; 2021; 28():10732748211021078. PubMed ID: 34060373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.